Mar 09,2021

TrialJectory Achieves 500 Percent Year-Over-Year Growth

TrialJectory (now known as Leal Health), an artificial intelligence-powered digital health platform that empowers cancer patients to find advanced treatment options and enables the pharmaceutical industry to effectively design and recruit for clinical trials, announced today that it has experienced 500 percent year-over-year growth in new patient users, with approximately 3,000 new patients signing up each month.  The platform uses AI to curate, structure and personalize massive quantities of data produced by cancer research every day and makes the experience of being matched to the right clinical trial fast, accurate and patient-friendly.

PRODUCT

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Feb 07,2022

Trialjectory Raises $20 Million to Transform the Cancer Care Industry

Trialjectory (now known as Leal Health), the AI-powered decision-support platform for patients, healthcare providers and pharma, announced that it has raised  $20 million in a Series A round led by New York-based global private equity and venture capital firm Insight Partners, with participation from new investor JAL Ventures and from existing investors Contour Venture Partners, Rho Capital and TIA Ventures. Trialjectory will use the funding to transform cancer care by defining a new market category focused on delivering personalized, treatment decision-support and a new way for pharma to offer an authentic, patient-centered experience.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Mar 09,2023

Leal Health launches analytics platform to enhance recruitment to cancer trials

Artificial-intelligence-powered tech firm Leal Health rolled out its latest analytics program designed to help sponsors and trial sites develop patient-focused programs, improve recruitment and provide more operational efficiencies. The pitch from the company, formerly known as Trialjectory, is that the platform can integrate with a pharma or biotech’s existing online oncology clinical trial website. The company’s platform has had a digital finger in making more than 3.5 million treatment matches to date as well as adding over 4,000 new cancer patients to its rolls each month. Leal Health uses AI to match cancer patients with the right clinical trials for their exact diagnosis. The system integrates real-world data from other patients with similar medical profiles, treatments and outcomes, enabling oncologists to accurately inform prospective patients about their treatment options.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jun 20,2023

Leal Health Becomes Industry's First and Only Single Point of Access to FDA-Approved Treatments and Clinical Trials for Cancer Patients

Leal Health, formerly known as Trialjectory, an AI-powered treatment decision support platform that democratizes patient access to advanced cancer treatments and empowers the pharmaceutical and biotech industry to execute patient-centric clinical trials, announced today that it has expanded its platform to include FDA-approved cancer treatment decision support, becoming the industry's first and only tool that offers patients seeking the best treatment options a single point of access to all relevant FDA-approved, standard-of-care treatments and clinical trials.

PRODUCT

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Oct 16,2023 TOP STORY

FINEOS and Osara Health Partner to Enhance Cancer Care

FINEOS, the leading modern enterprise core software for the life, accident and health industry, has forged a partnership with Osara Health, a digital health platform founded by oncologists, to enhance the care experience for individuals dealing with cancer. The partnership will offer integration of additional services for cancer patients and caregivers to insurance carriers using the FINEOS Platform for group, voluntary, individual and absence. Osara Health’s Cancer Coach initiative has demonstrated significant ability to improve overall return-to-work rates by 73%, and average time to return to work by 16.5 weeks in a recent Australian study. Osara Health plans to replicate this study in the U.S. market over the coming months. The recently introduced Cancer Caregivers program provides services for caregivers, enabling them to sustain employment and maintain productivity.

COLLABORATION PARTNERSHIP

#institution

#virtual care

#coaching

View Analyst & Ambassador Comments
Go to original news
Oct 13,2023 TOP STORY

Coreline Soft to deploy AI lung cancer screening software in France

Coreline Soft has formalised its partnership with the radiology network imaGen to deploy its AI lung cancer screening solution in France. Its AVIEW LCS Plus software, which uses AI to detect and analyse cancerous lung nodules, emphysema, and calcium in the coronary artery, has recently been validated for routine clinical use at Imagerie Médicale des Deux Provinces (IM2P) and Imagerie Paris Centre (IPC), both member radiologist groups under imaGen. IM2P is a group of 62 radiologists practising at over 20 sites in the Côte d'Or and Jura regions, while IPC is a collective of 33 radiologists based in the French capital.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 10,2023 TOP STORY

Mayo Clinic's AI Innovation Inspires Hope in Early Detection of Pancreatic Cancer

In a recent breakthrough, Mayo Clinic Comprehensive Cancer Center researchers used the world's most extensive imaging dataset to build a versatile artificial intelligence (AI) model that has shown the potential for autonomous detection of pancreatic cancer on standard CTs when surgical intervention can still promise a cure. The group developed a highly accurate AI model, trained on the largest - more than 3,000 patients - and most diverse CT dataset, for fully automated cancer detection, including small and otherwise difficult-to-detect tumors. Published in Gastroenterology, the journal of the American Gastroenterological Association, the study not only builds on the group's recent work on radiomics-based early detection models but also underscores Mayo Clinic's standing as a beacon of innovation in AI healthcare solutions.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 20,2021

Successful implementation of an ePRO remote monitoring system in patients receiving chemotherapy in a community oncology practice

Remote symptom monitoring of patients receiving cancer treatment has been shown to improve patient outcomes in the research setting. However, there is little evidence that this technology can be implemented and scaled in the real world with the same benefits. Beginning in June 2020, Highlands Oncology Group (HOG) offered patients receiving parenteral cancer therapy enrollment onto Expain: an EMR-integrated, electronic patient-reported outcomes (ePRO) system which enables remote symptom monitoring during systemic cancer therapy. From June 2020 – January 2021, HOG treated 1261 patients with IV chemotherapy. 769 patients were offered enrollment and 569 (73.9%) were successfully enrolled onto the ePRO system. REsults show that ePRO-based remote monitoring of patients receiving parenteral cancer therapy in routine clinical care is feasible. Patient enrollment and retention are high across all tumor types. Symptoms reported by patients were concordant with previous publications, and a small percent (7% of reports) required an acute office visit.

CLINICAL STUDY

#rpm

View Analyst & Ambassador Comments
Go to original news
Oct 10,2023 TOP STORY

How AI is reshaping cancer care and diagnosis

At the Constellation Forum 2023 at Northwell Health, a panel discussed the profound implications of artificial intelligence (AI) in oncology. The panelists recognized the potential of AI in oncology but emphasized the importance of transparency, accessibility, and addressing bias in AI systems for the benefit of patients and healthcare professionals. Dr. Richard Barakat, physician in chief and executive director of cancer services and research at Northwell Health, emphasized the use of AI in imaging as a clinical "copilot" to reduce errors, such as false negative mammograms. Andy Moye, CEO of Paige.AI, praised AI for improving diagnoses and reducing human error in oncology. His company digitizes analog instruments like glass slides, enabling the use of machine learning and AI. Daisy Wolf, an investing partner at Andreessen Horowitz, saw AI as a solution to manage rising healthcare costs by reducing clinicians' workload. 

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 09,2023 TOP STORY

Jasper Health’s CARE+ Gets HIPAA Compliant GenAI Upgrade, AskJasper

Jasper Health, an oncology supportive care and navigation platform, is unveiling AskJasper, an intelligent AI framework during HLTH’23, in Las Vegas. This upgrade provides a new layer of HIPAA compliant, Generative AI-augmented capabilities for its clinician-facing SaaS platform, Care+. With AskJasper, navigators, coaches, and healthcare professionals can generate supportive care plans tailored to each patient’s individual needs and close common care gaps such as stress management, nutrition, hydration, as well as medication organization and pain management skills. With chat assistance, navigators and supportive care teams can provide empathic support in real time. Jasper’s platform is used by large?? healthcare institutions including nation-leading Memorial Sloan Kettering Cancer Center (MSK).

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY